Results 21 to 30 of about 864 (131)
Reforming the provision of cross‐border medical care: Evidence from Spain
Health Economics, Volume 31, Issue 5, Page 859-876, May 2022., 2022 Abstract
Cross‐border medical care, defined as care facilitated by a local health provider under pre‐established regional agreements, as in the case of European Union (EU) citizens accessing care within EU countries, has been on the rise. Unlike medical tourism, typically sought by patients through their own volition and paid for out‐of‐pocket, cross ...Catalina Amuedo‐Dorantes, Noelia Rivera‐Garrido, Judit Vall Castelló +2 morewiley +1 more sourceEuropean patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the ESSCAA and the EBSB working groups of the ESCD, and the GEIDACC
Contact Dermatitis, Volume 86, Issue 5, Page 379-389, May 2022., 2022 Abstract Background
In 2019, a number of allergens (haptens), henceforth, “the audit allergens,” were considered as potential additions to the European Baseline Series (EBS), namely, sodium metabisulfite, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea, imidazolidinyl urea, Compositae mix II (2.5% or 5% pet), linalool hydroperoxides (lin‐OOH ...Wolfgang Uter, S. Mark Wilkinson, Olivier Aerts, Andrea Bauer, Leopoldo Borrego, Timo Buhl, Susan M. Cooper, Heinrich Dickel, Rosella Gallo, Ana M. Giménez‐Arnau, Swen M. John, Alexander A. Navarini, Maria Pesonen, Györgyi Pónyai, Thomas Rustemeyer, Sibylle Schliemann, Steffen Schubert, Marie‐Louise A. Schuttelaar, Skaidra Valiukevičienė, Nicola Wagner, Elke Weisshaar, Margarida Gonçalo, for the ESSCA and EBS ESCD working groups, and the GEIDAC +23 morewiley +1 more sourceDesafíos de medición para la investigación de la obesidad infantil en y entre América Latina y Estados Unidos
Obesity Reviews, Volume 22, Issue S5, Octubre 2021., 2021 Resumen
La obesidad infantil es un grave problema de salud pública en Latinoamérica y Estados Unidos y para luchar contra ella se precisan instrumentos de medición válidos y fiables y que tengan en cuenta los aspectos culturales. Para avanzar en este campo sería útil mejorar las mediciones en los distintos grupos de edades y países del continente ...David Berrigan, S. Sonia Arteaga, Uriyoán Colón‐Ramos, Lisa G. Rosas, Rafael Monge‐Rojas, Teresia M. O'Connor, Rafael Pérez‐Escamilla, Elizabeth F. S. Roberts, Brisa Sanchez, Martha Maria Téllez‐Rojo, Susan Vorkoper, the Cross Borders Working Group +11 morewiley +1 more sourceSector farmacéutico y el registro sanitario de uno de sus productos estrella
Catálogo editorial, 2022 La Compañía Transnacional Colombo-Peruana, con sede principal en Bogotá, hace parte del sector farmacéutico y pertenece a un grupo empresarial que se dedica a la comercialización, investigación y desarrollo de soluciones terapéuticas enfocadas a diferentes mercados de la salud de medicamentos. Esta empresa cuenta con presencia en más de cinco países en Juan Sebastián Cubillos-Urrego, Mayerly Burbano-Martínez, Johanna Patricia Romero-Lezama, Yurani Maritza Muñoz-Arenas, Edgar Bernal-Amaya, Manuel Méndez-Pinzón +5 moreopenaire +1 more sourceLa regulación del registro sanitario de medicamentos en Panamá
Revista Cathedra, 2019 En este documento se pretende establecer un juicio crítico de lo que existe en referencia a la Regulación de Registro Sanitario de Medicamentos, dándole inicialmente un enfoque desde el punto de vista del Derecho a la Salud, dentro del aspecto de la disponibilidad de medicamentos, abordando el concepto y definición de Registro Sanitario, el alcance ...openaire +1 more sourcePatch Test Results With Additions to the European Baseline Series, 2021/22—Joint European Results of the ESSCAA
and the EBSB
Working Groups of the ESCD, and the GEIDACC
Contact Dermatitis, Volume 95, Issue 3, Page 276-285, September 2026.ABSTRACT Background
Allergens are periodically added to the European Baseline Series (EBS) to audit their value in consecutive patch testing. Objectives
To present results of audit allergens tested in consecutive patients in 54 departments in 13 European countries during 2021 and 2022.Wolfgang Uter, Stephen Mark Wilkinson, Andrea Bauer, Leopoldo Borrego, Richard Brans, Timo Buhl, Heinrich Dickel, Rosella Gallo, Ana Giménez Arnau, Margarida Gonçalo, Dimitra Koumaki, Alexander A. Navarini, Cataldo Patruno, Györgyi Pónyai, Thomas Rustemeyer, Radoslaw Spiewak, Luca Stingeni, Skaidra Valiukevičienė, Marie‐L. A. Schuttelaar, Olivier Aerts, the ESSCA, EBS, ESCD working groups, the GEIDAC, Birger Kränke, Ella Dendooven, Dagmar Simon, Philip Spring, Ulrike Beiteke, Cecilia Dietrich, Sibylle Schliemann, Detlef Becker, Swen Malte John, Nicola Wagner, Elke Weisshaar, Stamatis Gregoriou, Maddalena Napolitano, Philippa Cousen, Graham A. Johnston, Juan Francisco Silvestre Salvador, José Manuel Carrascosa Carrillo, Mónica Munera Campos, Esther Serra Baldrich, Gemma Melé‐Ninot, Cristina Barrabés Torrella, David Pesqué, Ana María Giménez Arnau, María Antonia Pastor Nieto, Francisco Navarro Triviño, Leopoldo Borrego, Inmaculada Ruiz Gonzales, Enrique Gómez de la Fuente, Susana Córdoba Guijarro, Francisco Javier Ortiz de Frutos, Fátima Tous Romero, Tatiana Sanz Sánchez, Pablo Chicharro Manso, Marta Andreu Barasoain, Marta Elosua González, Araceli Sánchez Gilo, Paloma Sánchez‐Pedreño Guillén, Pedro Mercader‐García, Carmen Paredes Suárez, María Elena Gatica Ortega, José Juan Pereyra Rodríguez, Javier Miquel Miquel, Mercedes Rodríguez Serna, Violeta Zaragoza Ninet, Ricardo González Pérez +68 morewiley +1 more sourcePatch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCAA
and the EBSB
Working Groups of the ESCD, and the GEIDACC
Contact Dermatitis, Volume 95, Issue 1, Page 17-32, July 2026.ABSTRACT Background
Patch test results obtained with the European Baseline Series (EBS) in its current version serve both contact allergy surveillance and (re‐)assessing the diagnostic value of EBS allergens. Objectives
To present results of current EBS patch testing, obtained in 59 departments in 14 European countries during 2021 and 2022.Wolfgang Uter, S. Mark Wilkinson, Olivier Aerts, Andrea Bauer, Leopoldo Borrego, Richard Brans, Timo Buhl, Heinrich Dickel, Aleksandra Dugonik, Francesca Larese Filon, Ana Giménez Arnau, Cataldo Patruno, Györgyi Pónyai, Stamatis Gregoriou, Steffen Schubert, Dagmar Simon, Luca Stingeni, Skaidra Valiukevičienė, Elke Weisshaar, Thomas Werfel, Margarida Gonçalo, Marie‐L. A. Schuttelaar, ESSCAA and EBSB ESCD Working Groups, and the GEIDACC
, Birger Kränke, Alexander Navarini, Philip Spring, Ulrike Beiteke, Cecilia Dietrich, Sibylle Schliemann, Detlef Becker, Swen Malte John, Nicola Wagner, Dimitra Koumaki, Maddalena Napolitano, Anna Belloni Fortina, Francesca Larese Filon, Rosella Gallo, Thomas Rustemeyer, Radoslaw Spiewak, Maja Kalac Pandurovic, Tanja Kmecl, Mojca Simončič Godnič, Nada Kecelj, Philippa Cousen, Ella Dendooven, Juan Francisco Silvestre Salvador, José Manuel Carrascosa Carrillo, Mónica Munera Campos, Esther Serra Baldrich, Gemma Melé‐Ninot, Cristina Barrabés Torrella, David Pesqué, María Antonia Pastor Nieto, Francisco Navarro Triviño, Inmaculada Ruiz Gonzales, Enrique Gómez de la Fuente, Susana Córdoba Guijarro, Francisco Javier Ortiz de Frutos, Fátima Tous Romero, Tatiana Sanz Sánchez, Pablo Chicharro Manso, Marta Andreu Barasoain, Marta Elosua González, Araceli Sánchez Gilo, Paloma Sánchez‐Pedreño Guillén, Pedro Mercader‐García, Carmen Paredes Suárez, María Elena Gatica Ortega, José Juan Pereyra Rodríguez, Javier Miquel Miquel, Mercedes Rodríguez Serna, Violeta Zaragoza Ninet, Ricardo González Pérez +73 morewiley +1 more sourceLow‐intervention clinical trials in Spain: Do they progress?
British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1438-1444, May 2026.Abstract Aims
Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...Claudia Erika Delgado‐Espinoza, Mayro J. Cortés Pestana, Kristopher Amaro, Rosa M. Antonijoan, Caridad Pontes +4 morewiley +1 more sourceLegal perspectives on black box recording devices in the operating environment
BJS (British Journal of Surgery), Volume 106, Issue 11, Page 1433-1441, October 2019., 2019 A video and medical data recorder in the operating theatre is possible, but concerns over privacy, data use and litigation have limited widespread implementation. Transparency on the use and purpose of the recorded data should be ensured to both staff and patients. Clear legislation on data responsibility is needed to use the medical recorder optimally A. S. H. M. van Dalen, J. Legemaate, W. S. Schlack, D. A. Legemate, M. P. Schijven +4 morewiley +1 more source